ChemMedChem is a monthly peer-reviewed medicinal chemistry journal. It is co-owned by the 14 European chemical society members of ChemPubSoc Europe and is published by Wiley-VCH. Its 2010 impact factor is 3.306. In addition to original research in the form of full papers and shorter communications, ChemMedChem contains review-type articles (reviews, minireviews, essays, highlights) as well as occasional book reviews and conference reports. The first volume was published at the beginning of 2006 under the two founding chemical societies, the German Chemical Society (GDCh) and the Italian Chemical Society (SCI). Since then, 12 additional chemical societies have joined in co-ownership of the journal. ChemMedChem is a sister publication to other scientific journals published by Wiley-VCH, including Angewandte Chemie, ChemBioChem, ChemPhysChem, ChemSusChem, and ChemCatChem. Topics covered in ChemMedChem include drug design, development and delivery, molecular modeling, combinatorial chemistry, drug target validation, lead generation, and ADMET studies.

Impact factor
3.306 (2010)

Some content from Wikipedia, licensed under CC BY-SA

Unlocking the doors to effective COVID-19 treatments

A team of interdisciplinary researchers from the Institut National de la Recherche Scientifique (INRS) is hoping to identify effective COVID-19 therapeutics. With help from the Canadian Light Source (CLS) at the University ...

Researchers find inhibitors effective against a coronavirus enzyme

While the first vaccines have been developed against the pathogen SARS-CoV-2, studies are still underway to identify effective drugs for treating coronavirus infections. Scientists in Gießen, Mainz, and Würzburg in Germany ...

Englerin analogues with anti-cancer activity

The research group of Prof. Antonio M. Echavarren at ICIQ has designed and synthetized a series of analogues of (-)-Englerin A that are highly selective and effective in the growth-inhibition of renal cancer cells.

Small molecule slows down ticking of the biological clock

A group of biologists, theoretical chemists and synthetic chemists at ITbM have come together to develop a small molecule that slows down the circadian clock rhythm through binding to the CRY clock protein.

Brain tumor cells decimated by mitochondrial 'smart bomb'

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists.

Blocking African sleeping sickness' tiny culprit

A tsetse fly bites a girl. She becomes itchy, feverish, and her joints ache. Weeks later, she loses coordination and some sensation in her limbs. It becomes difficult to think, to sleep.

page 1 from 2